,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Dr. William G. Rice Ph.D.', 'age': 63, 'title': 'Chairman, Pres, CEO & Chief Accounting Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 920799, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
1,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Mr. Fletcher  Payne', 'age': 59, 'title': 'Sr. VP, CFO & Sec.', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 571087, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
2,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Dr. Rafael  Bejar M.D., Ph.D.', 'age': 50, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 668381, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
3,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Mr. Philippe  Ledru', 'age': 55, 'title': 'Sr. VP & Chief Commercial Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 644242, 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
4,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Mr. Roger  Davies B.Sc.', 'title': 'VP of Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
5,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Dr. Marc  Wiles Ph.D.', 'title': 'Sr. VP of Regulatory Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
6,251 Consumers Road,Suite 1105,Toronto,ON,M2J 4R3,Canada,647-479-9828,https://www.aptose.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.",35,"{'maxAge': 1, 'name': 'Mr. Brooks  Ensign M.B.A.', 'title': 'VP & Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",9,8,9,7,9,1693526400,1672444800,86400,4,4.55,4.55,4.51,4.55,4.55,4.55,4.51,4.55,0.0,1.471149,-0.5730623,2645,2645,1732,1790,1790,4.5,4.93,33040172,3.77,16.2,5.4722,9.8364,0.0,0.0,CAD,7299596,0.0,5561791,7325980,9912,13042,1690761600,1693440000,0.0015,0.02665,0.27633,4.12,0.0015,7325980,2.162,2.0860317,1672444800,1703980800,1688083200,-47582000,-10.25,-7.87,1:15,1686009600,-0.149,-0.669597,0.14113986,TOR,EQUITY,APS.TO,APS.TO,APTOSE BIOSCIENCES INC,Aptose Biosciences Inc.,830439000,America/Toronto,EDT,26481d47-a949-398f-9598-4711fcf7ed94,finmb_121269,-14400000,4.51,100.13,100.13,100.13,100.13,1.7,buy,1,23306000,3.575,-48869000,1204000,1.947,2.11,8.733,-0.66996,-1.37369,-23043624,-40425000,0.0,0.0,0.0,USD,
